Literature DB >> 1459225

Systemic tocainide relieves mechanical hypersensitivity and normalizes the responses of hyperexcitable dorsal horn wide-dynamic-range neurons after transient spinal cord ischemia in rats.

J X Hao1, Y X Yu, A Seiger, Z Wiesenfeld-Hallin.   

Abstract

In the present study we examined the effect of systemic tocainide on sensory hypersensitivity in rats after spinal cord ischemia induced by a photochemical technique. After induction of spinal cord ischemia the rats exhibited a sensory disturbance which was mainly expressed as vocalization to innocuous cutaneous mechanical stimuli (allodynia) in the flank area during the following several days. Tocainide at 75 mg/kg i.p., but not 50 mg/kg i.p., significantly increased the vocalization threshold to mechanical pressure for 2 h. The effect of intraarterial (i.a.) tocainide on the responses of dorsal horn wide-dynamic-range (WDR) neurons to suprathreshold electrical stimulation of their receptive fields was also examined in normal rats and after transient spinal cord ischemia, at a time when the animals exhibited typical behavioral allodynia in the dermatomes innervated by the ischemic spinal segments. In normal rats, tocainide (50 mg/kg i.a.) strongly suppressed the responses of WDR neurons to C fiber input with lesser effect on A fiber input. In allodynic rats, tocainide suppressed the augmented A and C fiber mediated responses of WDR neurons to the extent that their responses were similar to those seen in normal rats without tocainide. There was no difference in the overall depression of A and C fiber mediated input by tocainide between normal and allodynic rats. The present results demonstrated the analgesic effect of systemic tocainide in relieving allodynia in rats and indicated that systemic local anesthetics, at doses that do not block nerve conduction, can be effective in suppressing dorsal horn WDR neuronal activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1459225     DOI: 10.1007/bf00231656

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  21 in total

1.  Xylocaine for the relief of postoperative pain.

Authors:  E E BARTLETT; O HUTSERANI
Journal:  Anesth Analg       Date:  1961 May-Jun       Impact factor: 5.108

2.  Photochemically induced spinal cord injury in the rat.

Authors:  B D Watson; R Prado; W D Dietrich; M D Ginsberg; B A Green
Journal:  Brain Res       Date:  1986-03-05       Impact factor: 3.252

3.  Sites and mechanisms of action of lidocaine upon the isolated spinal cord of the frog.

Authors:  M Kuno; S Matsuura
Journal:  Brain Res       Date:  1982-10-07       Impact factor: 3.252

4.  Allodynia-like effects in rat after ischaemic spinal cord injury photochemically induced by laser irradiation.

Authors:  X J Hao; J X Xu; H Aldskogius; Å Seiger; Z Wiesenfeld-Hallin
Journal:  Pain       Date:  1991-05       Impact factor: 6.961

5.  Analgesic responses to i.v. lignocaine.

Authors:  R A Boas; B G Covino; A Shahnarian
Journal:  Br J Anaesth       Date:  1982-05       Impact factor: 9.166

6.  Mexiletine for treatment of chronic painful diabetic neuropathy.

Authors:  A Dejgard; P Petersen; J Kastrup
Journal:  Lancet       Date:  1988 Jan 2-9       Impact factor: 79.321

7.  Intravenous lidocaine for the treatment of intractable pain of adiposis dolorosa.

Authors:  R L Atkinson
Journal:  Int J Obes       Date:  1982

8.  Chronic pain treatment with intravenous lidocaine.

Authors:  P Petersen; J Kastrup; I Zeeberg; G Boysen
Journal:  Neurol Res       Date:  1986-09       Impact factor: 2.448

9.  Clinical electrophysiologic effects of tocainide.

Authors:  J L Anderson; J W Mason; R A Winkle; P J Meffin; R E Fowles; L Peters; D C Harrison
Journal:  Circulation       Date:  1978-04       Impact factor: 29.690

10.  The effect of systemic tocainide, lidocaine and bupivacaine on nociception in the rat.

Authors:  Zsuzsanna Wiesenfeld-Hallin; Ulf Lindblom
Journal:  Pain       Date:  1985-12       Impact factor: 6.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.